Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00233610
Status:
COMPLETED
Last Update Posted:
2011-01-27
First Post:
2005-10-04
Brief Title:
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Comparative Trial of the Efficacy of Two Different Nolvadex NDX Dosing and Scheduling Regimens in Preventing Gynecomastia Induced by Casodex CDX 150 Monotherapy in Prostate Cancer Patients An Open Multicenter Phase III Trial
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastiamastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None